EPO Patent EP2026030634A2: Sustained Transgene Expression Fusion Polypeptides

ChangeBridge: EPO Bulletin - Biotech (C12N)

Published March 18th, 2026

Detected March 24th, 2026

Summary

The European Patent Office has published patent application EP2026030634A2 concerning sustained transgene expression fusion polypeptides. The application details specific fusion polypeptides and their uses, with inventors not yet designated.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP2026030634A2, titled "Sustained Transgene Expression of Imid-Responsive Peptide-Suicide Protein Fusion Polypeptides and Uses Thereof." This publication relates to novel fusion polypeptides designed for sustained transgene expression, potentially impacting biotechnology and pharmaceutical research and development.

This is a patent publication, not a regulatory rule or guidance. Therefore, there are no immediate compliance obligations or deadlines for regulated entities. Companies in the biotech and pharmaceutical sectors may wish to review the patent for potential intellectual property implications or research opportunities.

Source document (simplified)

← EPO Patent Bulletin

SUSTAINED TRANSGENE EXPRESSION OF IMID-RESPONSIVE PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES AND USES THEREOF

Publication EP2026030634A2 Kind: A2 Mar 18, 2026

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

C07K 14/47 20060101AFI20260208BHEP C12N 9/64 20060101ALI20260208BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →